Unscheduled bleeding in combined oral contraceptive users: focus on extended-cycle and continuous-use regimens

Martha Hickey, Sweta Agarwal

Abstract

Combined oral contraceptives (COCs) are highly effective when correctly used but unscheduled bleeding, which occurs fairly commonly during the early months, is disruptive for many women. The mechanisms underlying this bleeding are not fully understood. Several studies have shown that extended-cycle or continuous-use COCs are typically associated with higher initial rates of unscheduled bleeding than are conventional 21-day cyclical COCs. Some medicines, herbal supplements and smoking may increase unscheduled bleeding by interfering with estrogen metabolism. The most common cause of unscheduled bleeding is non-adherence to a prescribed COC regimen. Compliance can be improved by appropriate counselling of women about the possibility of unscheduled bleeding and the importance of adherence to the pill regimen. If abnormal bleeding persists beyond 3–4 months and causes such as incorrect usage can be ruled out, other causes should be considered.

Keywords combined oral contraceptives, continuous-use COCs, extended-cycle COCs, unscheduled bleeding

Introduction

Combined oral contraceptives (COCs) provide excellent contraceptive efficacy and also give many women improved cycle control, reduced cycle-related pain, and reduced volume of menstrual loss.1,2 Unscheduled bleeding requiring sanitary protection is a common side effect of COCs. Such bleeding occurs most commonly during the first 3 months of COC use3 but it may persist and continue to be disruptive and troublesome for many women.

There is increasing interest in the potential health and lifestyle benefits of extended-cycle or continuous-use COCs.4 Although these COC regimens are associated with higher initial rates of unscheduled bleeding compared with conventional 21-day cyclical COCs,5 for many women the benefits of reducing or even eliminating monthly bleeding may outweigh the inconvenience of such unscheduled bleeding. This review describes the occurrence, causes and management of unscheduled bleeding associated with COCs, particularly with regard to extended-cycle or continuous-use preparations.

Methods

Relevant articles were obtained through a PubMed search of the literature. Key search terms included “unscheduled bleeding” and “breakthrough bleeding” in combination with “combined oral contraceptive” or “combined oral contraception”.

Assessment of bleeding patterns

There is lack of uniformity in the analysis and reporting of bleeding patterns. Recognising this, the World Health Organization (WHO) issued recommendations in 1986 for the standardised collection, analysis and reporting of bleeding associated with contraceptive use in clinical studies. The WHO recommended the use of “reference periods” rather than cycles because of the variability in the length of menstrual cycles both within and between individual women. It was therefore proposed that bleeding outcomes be measured using reference periods of at least 90 days.6,7 Recently, Mishell and colleagues8 published new recommendations for the standardisation of data collection and analysis of bleeding in studies of hormonal contraception.

How prevalent is unscheduled bleeding and what causes it?

In studies of inadvertent pregnancies in COC users, the proportion of women who experienced unscheduled bleeding ranged from 16% to 21%.9,10 A recent literature review suggested that irregular bleeding is most common during the first cycle of COC use and that this decreases with longer-term use and strict compliance. The number of bleeding/spotting days for all COCs ranged between 10 and 24 days for the first 90-day reference period but decreased to between 7.5 and 15 days by reference period 4.11

For women from many different cultures, regular patterns of vaginal bleeding are central to beliefs concerning fertility, absence of pregnancy and reproductive health. For some women, the presence of irregular or unpredictable bleeding is a barrier to social, sexual and cultural activities.

Key message points

- Unscheduled bleeding is a common side effect of combined oral contraceptives (COCs).
- Women should be counselled appropriately about the possibility of unscheduled bleeding and the importance of adherence to a pill regimen.
- Those considering extended-cycle or continuous-use regimens should be advised that unscheduled bleeding may be more common in the first 3–4 months of use.
- A short, hormone-free interval may be an effective clinical management strategy for disruptive unscheduled bleeding in women on continuous COC regimens.
- Persistent or new-onset unscheduled bleeding may be due to incorrect usage or to cervical or other pathology.
and hence represents a major disruption to their lives. In some societies due to social traditions there may be restriction of social, religious or domestic activities during the days of bleeding. Unscheduled bleeding with COCs may be sufficiently troublesome to lead some women to discontinue their use. In a study of 1657 women starting or restarting COCs in the USA, 12% of subsequent discontinuations were attributed to bleeding irregularities.12

COCs comprise an estrogen component [typically ethinylestradiol (EE)] and a progestogen component. The trend in COC formulations has been towards lower doses of both sex steroids, but lower doses of estrogen may be insufficient to sustain endometrial support, leading to unscheduled bleeding.13 In a study comparing COCs containing the same amount of progestogen with two different doses of EE, the formulation containing less EE was associated with a higher incidence of unscheduled bleeding.14 However, progestogen-induced decidualisation and endometrial atrophy may also contribute to the problem.5

Do variations in COC formulation or regimen affect the occurrence of unscheduled bleeding?

In addition to the dose of sex steroid hormones, the formulation and regimen of COCs may affect the incidence of unscheduled bleeding. In a study that compared two COCs, one containing 20 µg EE and 100 µg levonorgestrel (LNG) or 500 µg norethisterone, the frequency of unscheduled bleeding was significantly less with LNG.15 There is also evidence that the ratio of estrogen to progestogen may affect the incidence of unscheduled bleeding.16

Prescribing schedules may also be important. Extended-cycle or continuous-use COCs are typically associated with higher initial rates of unscheduled bleeding than are conventional 21-day cyclical COCs.5 One study randomised women (n = 682) to receive a COC containing 150 µg LNG and 30 µg EE according to an extended-cycle regimen (84 days of active pills followed by a 7-day hormone-free interval) or a conventional cyclical regimen (21 days of active pills followed by a 7-day hormone-free interval) over 1 year.5 Women on the extended-cycle regimen reported a mean 37.6 (11% of 336 possible days) unscheduled bleeding/spotting days vs 18.3 (7% of 273 possible days) for women on the conventional regimen. In a separate study, 708 women were treated with a 91-day extended-cycle COC (150 µg LNG/30 µg EE).17 Each cycle consisted of 84 days of active pills followed by 10 mg EE daily for 7 days. The mean number of unscheduled bleeding/spotting days was highest during each cycle (21/12), missed pills resulted in an episode of unscheduled bleeding.13 In a study comparing COCs for daily use without a hormone-free interval.18 It has recently been approved by the US Food and Drug Administration and is currently being evaluated by the European Medicines Agency. Over the 1-year trial (13 pill packs), the number of bleeding and spotting days per pill pack declined progressively; by pill pack 6 and 13, the incidence of bleeding was 33% and 21%, respectively. In a separate trial (n = 641) conducted over 12 months, women were randomised to receive 13 packs of cycle-free LNG/EE or a 21-day cyclical COC (LNG 100 µg EE 20 µg).19 Among the women who received cycle-free LNG/EE, the percentage who experienced unscheduled bleeding decreased with each pill pack (50% at pill pack 3 vs 21% at pill pack 13). After pill pack 4, the median number of days of unscheduled bleeding and/or spotting was lower with cycle-free LNG/EE than with the cyclical preparation.

How do concomitant medications and smoking affect the occurrence of unscheduled bleeding?

Medicines and herbal supplements that induce the cytochrome P450 enzyme system may affect the metabolism of COCs, reducing their efficacy and increasing the risk of unscheduled bleeding. These concomitant medications may include the antituberculosis agent rifampicin,20 antiretrovirals and St John’s Wort.21 A comprehensive review of the literature on drug interactions between COCs and antibiotics identified case reports suggesting a relationship between use of griseofulvin and the occurrence of oligomenorrhoea, irregular menses, and unplanned pregnancy.20 Smoking may increase the incidence of unscheduled bleeding by altering estrogen metabolism and consequently diminishing endometrial support.22 In a study that evaluated data from three trials (n = 2956) for six consecutive menstrual cycles, a significantly higher proportion of smokers reported unscheduled bleeding during each cycle (p ≤0.039).23 Smokers were 47% more likely to have unscheduled bleeding than non-smokers, with higher levels of smoking associated with a greater frequency of unscheduled bleeding.

What role does compliance play in unscheduled bleeding?

The most common cause of unscheduled bleeding is missed pills (non-adherence to a prescribed COC regimen). In a prospective study evaluating the effect of deliberate omission of two consecutive COC tablets (days 6/7 or days 11/12), missed pills resulted in an episode of unscheduled bleeding in 10 out of 12 cycles.24 Even delaying taking COCs for a few hours may increase the risk of unscheduled bleeding.22

Women generally admit to missing pills in far fewer self-reported cycles than if the pill-taking is objectively recorded. Potter et al.25 compared self-reported data on pill-taking with data from an electronic device measuring compliance. In 3 months of pill use, the electronic and self-reported data agreed on the number of days when pills were missed in only 45% of cases; the level of agreement dropped from 55% in the first month to 38% in the third month. In each month, the proportion of women reporting no missed pills was much higher than the proportion recorded electronically (53–59% compared with 19–33%), and the proportion missing at least three pills according to the electronic data was triple that derived from the women’s reports (30–51% vs 10–14%). In addition, the electronic data recorded substantially more episodes in which women missed pills on two or more consecutive days (88 vs 30). This study very clearly showed that ‘compliance’ was much worse than the individual women were prepared to admit.25

In a study of 943 women in the USA, those who reported unscheduled bleeding or spotting were 1.6 to 1.7 times more likely to have missed two or more pills per cycle than those who did not.26 In a study of 6676 women in Denmark, France, Italy, Portugal and the UK that examined adherence behaviour among OC users, 19% of the subjects stated that they generally miss one or more pills per cycle and 10% miss two or more.27 Moreover, women who did not have an established pill-taking routine were over three times more likely to miss pills compared...
with those with a routine. These women were also 4.6 times more likely to be among the group of women who missed two or more pills.

How important is proper patient counselling in managing unscheduled bleeding?
Correct COC use is influenced by the occurrence of side effects, the pill-taking routine, and whether a woman has read and/or understood relevant package information. Those women who are aware of the possibility of unscheduled bleeding before beginning a new COC prescription are more likely to tolerate short-term changes to their bleeding profile. However, side effects with COC are mild and are less important reasons for discontinuation than is widely believed.

The best way to ensure that women receive appropriate information about bleeding irregularities with COCs is proper patient counselling, particularly with regard to the importance of adherence to a prescribed pill regimen (Figure 1). This may minimise the risk of missed pills and the occurrence of unscheduled bleeding. Unfortunately, many women do not receive adequate counselling. Rosenberg et al. reported that nearly 50% of women said that they did not receive appropriate information from their health care provider when their COC was first prescribed. These women were approximately 1.5 times more likely to be inconsistent COC users than those who were satisfied with the counselling they received. A survey of knowledge about COCs in 649 women waiting at pharmacies to receive new prescriptions for COCs indicated that a significant proportion of the women had not been counselled about common side effects of COCs. For instance, 65.5% and 46.1% of women had not been counselled about unscheduled bleeding and missed pills, respectively. Those who had been counselled had higher levels of understanding about COCs. There may also be disparities between the information that physicians believe they are providing about COCs and what patients report that they have been told. Written information may be useful in this regard.

How should providers counsel patients regarding unscheduled bleeding, particularly with regard to extended-cycle and continuous-use COCs?
Patient counselling should include information about the potential for unscheduled bleeding, a clear explanation of how to take the COC, information about the possible consequences of missed or delayed pills, and the benefits of a pill-taking routine. Providers should stress the likely transient nature of unscheduled bleeding and encourage questions, particularly for those women who are first-time COC users or who have not used COCs recently.

Although unscheduled bleeding during the first 3–4 months of cyclical COC use is common, extended-cycle or continuous-use COCs may be associated with a longer duration of unscheduled bleeding as well as higher rates in the initial months of use. Women considering extended-cycle or continuous-use COCs should be counselled about the need to weigh the convenience of no (or fewer) planned bleeds against the inconvenience of increased unscheduled bleeding. The benefit of a pill-taking routine should be emphasised.

Providing clear and appropriately targeted educational materials regarding the proper use of COCs, particularly written information, is useful and also used by patients. This has a significant impact on raising awareness and increasing contraceptive knowledge and many of these resources are available online.

Are there any clinical strategies to manage unscheduled bleeding with extended-cycle and continuous-use COCs?
Currently, there is little evidence from well-designed, randomised studies on clinical strategies for the management of unscheduled bleeding associated with extended-cycle and continuous-use COCs. However, a recent prospective study assessed the occurrence and management of unscheduled bleeding during continuous use of a COC (drospirenone 3 mg/EE 30 µg) over 168 days. Instituting a 3-day hormone-free interval was more effective in resolving unscheduled bleeding/spotting than was continuing active pills (p<0.0001).

What should be done for prolonged unscheduled bleeding?
If unscheduled bleeding on COCs persists beyond 3–4 months and causes such as incorrect usage can be ruled out, pathological or physiological causes should be considered. In women with persistent unscheduled bleeding or spotting on a COC and in whom pathological causes have been excluded, we usually recommend changing to another formulation. One study of 65 COC users with unscheduled bleeding found that 29.2% tested positive for endocervical Chlamydia trachomatis, compared with 10.7% in matched controls. Thus persistent unscheduled bleeding warrants physical examination to rule out any local lower genital tract causes such as cervical ectropion and invasive cervical cancer, and appropriate investigations should be instituted based on the history and examination findings. Possible upper genital tract causes of unscheduled bleeding include endocervical or endometrial infection, endocervical cancers, endometrial polyps, submucous myomas, cervical cancer and pelvic inflammatory disease.

Unscheduled bleeding is a common unwanted effect of combined oral contraceptives and may occur with all regimens. Clinicians should be aware that appropriate counselling and continuing support may improve compliance, and should remember to rule out pathology as a cause of the bleeding.

References
Hickey and Agarwal/Book review

2 Breakthrough bleeding number one problem with OC use.

2010.

3 Schrager S, Blackwell N, Gill Wakley, MD, FFSRH
Retired Professor of Primary Care Development
and Freelance Writer, Abergavenny, UK
BOOK REVIEW

2 Breakthrough bleeding number one problem with OC use.

2010.

517–522.

6 Mishell DR Jr, Guillebaud J, Westhoff C, Nelson AL, Kaunitz
AM, Trussell J, Curtin JA, Irwig L, Stubblefield K, Trussell

7 Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W.
Multicenter, comparative study of cycle control, efficacy and
tolerability of two low-dose oral contraceptives containing 20
microg ethinylestradiol/100 microg levonorgestrel and 20 microg
ethinylestradiol/500 microg norethisterone.

8 Mishell DR Jr, Guillebaud J, Westhoff C, Nelson AL, Kaunitz
AM, Trussell J, et al. Recommendations for standardization of
data collection and analysis of bleeding in combined hormone
contraceptive trials.

9 Sparrow MJ. Pill method failures.

10 Kovacs GT, Riddoch G, Duncombe P, Welsberry L, Chipp P,
Weissberg E, et al. Inadvertent pregnancies in oral
contraceptive trials.

11 Bachmann G, Koner P. Bleeding patterns associated with oral
contraceptive use: a review of the literature.

12 Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation:
a prospective evaluation of frequency and reasons.

13 Kaunitz AM. Oral contraceptive estrogen dose considerations.

14 Akerlund M, Rode A, Westegaard J. Comparative profiles of
reliability, cycle control and side effects of two oral
contraceptive formulations containing 150 micrograms
desogestrel and either 50 micrograms or 20 micrograms ethinyl
estradiol.

15 Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W.
Multicenter, comparative study of cycle control, efficacy and
tolerability of two low-dose oral contraceptives containing 20
microg ethinylestradiol/100 microg levonorgestrel and 20 microg
ethinylestradiol/500 microg norethisterone.

16 Lawson JS, Yuliano SE, Pasquale SA, Osterman JJ. Optimum
dosage of an oral contraceptive. A report from the study of
seven combinations of norgestrel and ethinyl estradiol.

17 Anderson FD, Gibbons WT, Portman D. Safety and efficacy of an
extended-regimen oral contraceptive utilizing continuous low-
dose ethinyl estradiol.

18 Archer DF, Jensen JT, Johnston SL, Delta T, Grubb GS.

19 Teichmann AT, Kullt C, Grubb GS, Constantin G, Spielmann D.
Comparative trial of continuous-use and 21-day cyclic
levonorgestrel and ethinyl estradiol oral contraceptive.

20 Dickinson BD, Altman RD, Nielsen NH, Sterling ML. Drug
interactions between oral contraceptives and antibiotics.

21 Murphy PA, Kern SE, Stanczyz FK, Westhoff CL. Interaction of
St. John’s Wort with oral contraceptives: effects on the
pharmacokinetics of norethindrone and ethinyl estradiol,
coagulation activity and breakthrough bleeding.

22 Darney PD. OC practice guidelines: minimizing side effects.

23 Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle
control among oral contraceptive users.

24 Endrikat J, Wessel J, Rosenberg MJ, Waugh MS, Dusterberg B.
Plasma concentrations of endogenous hormones during one
regular menstrual cycle and two cycles with deliberate omission of two tablets.

25 Potter L, Oakley D, de Leon-Wong E, Caframin R. Measuring
compliance among oral contraceptive users.

26 Rosenberg MJ, Waugh MS, Burnhill MS. Compliance,
counselling and satisfaction with oral contraceptives: a
prospective evaluation.
Fam Plann Perspect 1996; 30: 89–92, 104.

27 Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral
contraceptives: risk indicators for poor pill taking and
discontinuation.
Contraception 1995; 52: 137–141.

28 Belsey EM. The association between vaginal bleeding patterns and
reasons for discontinuation of oral contraceptive use.

29 Westhoff CL, Heartwell S, Edwards S, Zieman M, Stuart G,
effects matter?

30 Gaudet LM, Kives S, Hahn PM, Reid RL. What women believe
about oral contraceptives and the effect of counselling.

31 Rajasekar D, Bigrigg A, Docherty G. Nationwide audit of pill
knowledge amongst family planning users in Scotland.

32 Nelson AL. Communicating with patients about extended-cycle and
continuous use of oral contraceptives.

33 Little P, Griffin S, Kelly J, Dickson N, Sadler C. Effect of
educational leaflets and questions on knowledge of
contraception in women attending the combined
oral contraceptive pill: randomised controlled trial.

34 Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of
occurrence and management of breakthrough bleeding during an
extended oral contraceptive regimen.

35 Krettek JE, Arkin SI, Chaislilawattana P, Monir GR. Chlamydia
trachomatis in patients who used oral contraceptives and had
intermenstrual spotting.

BOOK REVIEW


This is the slightly revised third edition of an excellent publication that I recommend to anyone thinking about writing an article and getting it published. The style is commendably clear and the author is encouraging, which is unusual for books about writing. As the author says, look at why you want to write and what you need to write, sit down and do it. It does not take long, but it is work.

The book is laid out, as in the previous editions, following the 10-stage process that goes from the first idea to after publication. Throughout the author points out that writing is not a difficult process, but should be regarded as producing a good product and marketing it well. If only more authors followed Tim Albert’s advice about setting their brief out clearly before starting writing! The brief he recommends contains five steps: the message, the market, the length, the deadline and the co-authors. All authors too often, reviewing articles reveals that the authors have not stated the message they wish to convey. If they don’t know, how will their readers? Many articles arrive at a journal clearly originally intended for another or without having consulted the authors’ instructions – another ‘must’ Tim Albert outlines. Clarity of thought and writing is helped by looking at the following suggested questions: Why did we start? What did we do? What did we find? What does it all mean?

It is difficult to pick out points to illustrate the worth of the book – to do so would involve an unnecessary reproduction of the contents of each chapter. For example, another of the things that irritates reviewers is when authors quote the findings of papers incorrectly. Tim Albert recommends that authors should actually read the references that they quote! To nitpick, I found the summary of achievements that appear at the end of each chapter slightly incongruous in a book; they are more applicable to course material (to convince the funders that you know what you are doing!).

If you want to write articles, this is an excellent starting point. If you already write successfully, read it to improve your technique.

Reviewed by Gill Wadley, MD, FFSRH
Retired Professor of Primary Care Development and Freelance Writer, Abergavenny, UK

©FSRH J Fam Plann Reprod Health Care 2009: 35(4)
Unscheduled bleeding in combined oral contraceptive users: focus on extended-cycle and continuous-use regimens

Martha Hickey and Sweta Agarwal

J Fam Plann Reprod Health Care 2009 35: 245-248
doi: 10.1783/147118909789587411

Updated information and services can be found at:
http://jfprhc.bmj.com/content/35/4/245

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/